Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A A Hombach

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Gene Therapy|October 15, 2010
CD28 cosignalling does not affect the activation threshold in a chimeric antigen receptor-redirected T-cell attackM Chmielewski, A A Hombach, H Abken
Current Molecular Medicine|November 3, 2012
The weal and woe of costimulation in the adoptive therapy of cancer with chimeric antigen receptor (CAR)-redirected T cellsA A Hombach, A Holzinger, H Abken
Gene Therapy|June 18, 2010
Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune responseA Hombach, A A Hombach, H Abken
Gene Therapy|July 1, 2016
A dual chain chimeric antigen receptor (CAR) in the native antibody format for targeting immune cells towards cancer cells without the need of an scFvE Faitschuk, V Nagy, A A Hombach, et al.
Gene Therapy|June 26, 2009
Redirecting human CD4+CD25+ regulatory T cells from the peripheral blood with pre-defined target specificityA A Hombach, D Kofler, G Rappl, et al.
Gene Therapy|March 2, 2012
T cells redirected by a CD3ζ chimeric antigen receptor can establish self-antigen-specific tumour protection in the long termM Chmielewski, G Rappl, A A Hombach, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Gene Therapy|October 15, 2010
CD28 cosignalling does not affect the activation threshold in a chimeric antigen receptor-redirected T-cell attackM Chmielewski, A A Hombach, H Abken
Current Molecular Medicine|November 3, 2012
The weal and woe of costimulation in the adoptive therapy of cancer with chimeric antigen receptor (CAR)-redirected T cellsA A Hombach, A Holzinger, H Abken
Gene Therapy|June 18, 2010
Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune responseA Hombach, A A Hombach, H Abken
Gene Therapy|July 1, 2016
A dual chain chimeric antigen receptor (CAR) in the native antibody format for targeting immune cells towards cancer cells without the need of an scFvE Faitschuk, V Nagy, A A Hombach, et al.
Gene Therapy|June 26, 2009
Redirecting human CD4+CD25+ regulatory T cells from the peripheral blood with pre-defined target specificityA A Hombach, D Kofler, G Rappl, et al.
Gene Therapy|March 2, 2012
T cells redirected by a CD3ζ chimeric antigen receptor can establish self-antigen-specific tumour protection in the long termM Chmielewski, G Rappl, A A Hombach, et al.
Pageof 1